U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its ...

Medicaid spent an estimated $551.8 million in 2024 on GSK’s authorized generic inhaler, nearly double the expected cost with Flovent HFA. Hospitalizations for asthma spiked 24.1% in the six ...

Flovent HFA had long been the most prescribed controller inhaler for young children with asthma. After it was removed from the market in January 2024, GSK partnered with Prasco Laboratories to ...

GSK (GSK) faces an investigation from U.S. Senator Maggie Hassan over its decision to discontinue Flovent HFA asthma inhaler ...

U.S. Senator Maggie Hassan has initiated an investigation into GlaxoSmithKline's decision to discontinue the Flovent HFA ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant ...

Amid ongoing controversy, Sen. Maggie Hassan (D-N.H.) is investigating GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid paying ...

Hassan, the top Democrat on the Senate Finance Committee's Health Care Subcommittee, called on GSK to restore the inhaler to market. She also requested internal pricing documents, rebate data and ...